Table 5.

Chemoradiation Results Using Bone-Seeking Radiopharmaceuticals

Study, yr (Phase, n)	Treatment	Response	Survival (mos)
Pagliaro et al.,40 2003 (I/II, 15)	89Sr 55 mCi/kg +	13% (PSA≤50%)	8
	Gemcitabine 800 mg/m2 ×6
Lam et al.,39 2009 (I, 12)	188Re 37 MBq/kg +	NR	NR
	Capecitabine ≤2,500 mg/m2/d
Sciuto et al.,53 1996 (RII, 30)	89Sr 148 MBq +	58% (pain relief)	5.7
	Carboplatin 100 mg/m2 d1, 21	87%, P=.025	8.1
Mertens et al.,36 1992 (II, 17)	89Sr 148 MBq +		8+
	Cisplatin 35 mg/m2	55% (pain relief)
Sciuto et al.,54 2002 (RII, 70)	89Sr 148 MBq +	63% (pain relief)	6
	Cisplatin 50 mg/m2	91%, P<.01	9
Tu et al.,55 1996 (I/II, 25)	89Sr 55 μCi/kg ≤3 +	32% (PSA≤75%)	15
	Doxorubicin 20 mg/m2 ≤×20
Tu et al.,10 2001 (RII, 72)	89Sr 55 μCi/kg, s/p KAVE +	7 mo (TTP)	17
	Doxorubicin 20 mg/m2 ×6	14 mo, P<.001	28, P=.001
Akerley et al.,56 2002 (II, 44)	89Sr 2.2 MBq/kg +	48% (PSA≤50%)	13
	Vinblastine 4 mg/m2/estram ×8
Amato et al.,44 2008 (II, 29)	89Sr 148 MBq +	78% (PSA≤50%)	23
	KATE
Fizazi et al.,45 2009 (II, 43)	153Sm-EDTMP 37 MBq/kg, s/p	77% (PSA≤50%)	29
	Docetaxel/estram +
	Docetaxel 20 mg/m2 ×6
Tu et al.,57 2009 (I, 18)	153Sm-EDTMP 1 mCi/kg ×2 +	28% (PSA≤50%)	NR
	Docetaxel ≤35 mg/m2 d1, 8, 15
Morris et al.,58 2009 (I, 28)	153Sm-EDTMP 1 mCi/kg ≤×6 +	54% (PSA≤50%)	NR
	Docetaxel ≤75 mg/m2 ≤×13

RII, randomized phase II; PSA, prostate-specific antigen; KATE, ketoconazole combined with doxorubicin alternating with estramustine combined with paclitaxel;

KAVE, ketoconazole combined with doxorubicin alternating with estramustine combined with vinblastine; EDTMP, ethylenediaminetetramethylene phosphonic acid; TTP, time-to-progression; NR, not reported